Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Development of “Covalent Antibody Recruiting Molecules” Tumor Immunotherapeutics
FY 2020-21
Summary
A person's immune system is excellent at recognizing and killing diseases, but sometimes diseases are able to hide or block the immune system from killing it. Immunotherapy uses a person's immune system to better recognize and fight diseases such as cancer. A growing strategy in immunotherapy is to use Antibody Recruiting Molecules (ARMs). These work by directing natural antibodies in the blood to the surface of cancer cells. Antibodies coating the cancer cell acts as a molecular ""flag"" helping the immune system find and destroy the cancer. ARM function depends on their ability to contact antibodies and the surface of cancer cells simultaneously. While promising ARMs have 2 major problems. The first is since they are small, the body clears them in a few hours, limiting the amount in the body. The second is for an ARM to work, the immune system, antibody, ARM, and cancer all have to be associated simultaneously for long enough time for the immune system to kill the cancer. Both these problems limit how well they can work. To solve these problems, I propose creating Covalent Antibody Recruiting Molecules (cARMs). These are identical to ARMs, but have one extra part. This extra part enables ARMs to permanently link to the antibody, resulting in more efficient coating of the cancer cell with antibodies to enhance immune recognition. Additionally, the ARM cannot be cleared from the body as quickly. Because of these changes we can learn more about the mechanisms behind how the immune system kills cancer by comparing cARMs to ARMs. In addition, cARMs may work as a new immunotherapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449819
Name
Kapcan Eden
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of “Covalent Antibody Recruiting Molecules” Tumor Immunotherapeutics
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibody Recruiting Molecule; Covalent Proximity Inducing Molecules; Immune Recognition Of Cancer; Immune Synapse; Immunotherapy
Abstract
A person's immune system is excellent at recognizing and killing diseases, but sometimes diseases are able to hide or block the immune system from killing it. Immunotherapy uses a person's immune system to better recognize and fight diseases such as cancer. A growing strategy in immunotherapy is to use Antibody Recruiting Molecules (ARMs). These work by directing natural antibodies in the blood to the surface of cancer cells. Antibodies coating the cancer cell acts as a molecular ""flag"" helping the immune system find and destroy the cancer. ARM function depends on their ability to contact antibodies and the surface of cancer cells simultaneously. While promising ARMs have 2 major problems. The first is since they are small, the body clears them in a few hours, limiting the amount in the body. The second is for an ARM to work, the immune system, antibody, ARM, and cancer all have to be associated simultaneously for long enough time for the immune system to kill the cancer. Both these problems limit how well they can work. To solve these problems, I propose creating Covalent Antibody Recruiting Molecules (cARMs). These are identical to ARMs, but have one extra part. This extra part enables ARMs to permanently link to the antibody, resulting in more efficient coating of the cancer cell with antibodies to enhance immune recognition. Additionally, the ARM cannot be cleared from the body as quickly. Because of these changes we can learn more about the mechanisms behind how the immune system kills cancer by comparing cARMs to ARMs. In addition, cARMs may work as a new immunotherapy.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kapcan, Eden
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~